Concerns have been raised over patient choice and access to up-to-the-minute procedures as Southern Cross Health Society (SCHS) has chosen not to approve the latest high-tech minimally invasive glaucoma surgery (MIGS) devices for glaucoma sufferers.
SCHS’s decision to deny policyholders access to MIGS devices, including the increasingly popular trabecular micro-bypass stents, used in the public health system and funded by other private health insurers, has left Kiwi ophthalmologists frustrated and prompted glaucoma groups to speak out.
Dr Stephen Child, chief medical officer, Southern Cross Health Society (SCHS) said, “Following extensive evidence-based and independent reviews, SCHS has decided not to approve the addition of MIGS as a funded procedure under our health insurance plans at this time.
“Given our status as a not-for-profit Friendly Society existing solely for the benefit of members, Southern Cross carefully considers the health outcomes and cost efficiencies offered by new technologies or treatments before introducing cover for them into our plans. While we recognise there is some proven value in MIGS, we have prioritised new funding for technologies we believe offer better value for our members at this time.”
In a statement, SCHS said its decision was based on its own assessment and an external review by Best Doctors, an international insurance company-affiliated organisation described by its New Zealand manager, Mike Morris, as “a global provider of virtual care solutions”.
